Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

Local treatment, targeted at inhibition of interleukins 4 and 13 in the lung, could substantially diminish the symptoms of asthma.

S Wenzel，D Wilbraham，R Fuller，... - 《Lancet》

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

SummaryBackground Increases in T helper (Th) 2 cytokine concentrations have been seen in atopic asthma, with interleukin 4 and interleukin 13 thought to ha...

Sally，Wenzel，and，... - 《Lancet》

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.

This article reports on a clinical trial that looked at the effect of an interleukin-4 variant on last phase asthmatic response. Increases in Th2- cytosine...

Wenzel，Sally，Wilbraham，... - 《Lancet》

Effect of an interleukin-4 variant on late phase asthma response to allergen challenge in asthmatic patients: results of two phase II studies

Increases in T helper (Th) 2 cytokine concentrations have been seen in atopic asthma, with interleukin 4 and interleukin 13 thought to have a role in the p...

S Wenzel，D Wilbraham，R Fuller，... - 《Lancet》

MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS

not available for EP1660529of corresponding document: US2005059590 This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and...

PAN CLARK，ROCZNIAK STEVE，GREVE JEFFREY MICHAEL，...

Methods and compositions for treating asthma in human and nonhuman primates

The present invention relates generally to methods and compounds for treating pulmonary disorders, and more specifically to the inhalation administration and use of hIL-4 mutant proteins to treat asthma.

J Tepper，A Tomkinson

Methods and Compositions for Treating Asthma in Human and Nonhuman Primates

The present invention relates generally to methods and compounds for treating pulmonary disorders, and more specifically to the inhalation administration and use of hIL-4 mutant proteins to treat asthma.

J Tepper，A Tomkinson - US